MAPT and Alzheimer disease: We performed a pilot study investigating CSF iron and ferritin levels in patients with CAA, control subjects (CS) and patients with Alzheimer’s disease (AD), and how these correlated with other neurodegenerative CSF biomarkers (Aβ-40, Aβ-42, total tau, phospho-tau, and neurofilament light).